Skip to search formSkip to main contentSkip to account menu

doxorubicin-14-O-hemiadipate

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2002
2002
Previously, we have reported partial circumvention ofP-glycoprotein (Pgp)-associated resistance to doxorubicin(Dox) in MCF7/R… 
1989
1989
N-Trifluoroacetyladriamycin-14-O-hemiadipate (AD 143), a DNA nonbinding derivative of Adriamycin, was studied for its effect on… 
1987
1987
The N-acylanthracyclines AD32 (N-trifluoroacetyladriamycin-14-valerate) and AD143 (N-trifluoroacetyladriamycin-14-O-hemiadipate… 
1986
1986
The interaction of three second-generation anthracycline derivatives with polynucleotides, supercoiled DNA, and calf thymus… 
1986
1986
In connection with structure-activity studies related to the novel DNA-nonbinding adriamycin analogues N-(trifluoroacetyl… 
1986
1986
N-Trifluoroacetyladriamycin-14-O-hemiadipate (AD 143) is the most active among the 14-O-hemiester adriamycin-trifluoroacetamide… 
1986
1986
On the consideration that the highly active DNA-nonbinding adriamycin analogues N-(trifluoroacetyl)adriamycin 14-valerate and N… 
1985
1985
The effects of N-benzyladriamycin-14-valerate (AD198) and N,N-dimethyladriamycin-14-valerate (AD199), two novel lipophilic N…